Jun 02, 2020
Anti-Viral Therapies Market to Reach $46.21 Bn, Globally, by 2026 at 2.4% CAGR: Allied Market Research
May 22, 2020
Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)
Apr 08, 2020
Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19
Feb 27, 2020
Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Application, By Type, By Region And Segment Forecasts, 2020 - 2027
Feb 26, 2020
Global Antiviral Drugs Industry Insights, 2016-2019 & 2020-2027 - HIV Applications to Witness the Fastest Growth
Feb 17, 2020
Viriom to present results of Phase I study of the long acting injectable formulation of novel NNRTi for treatment of HIV-1 infection at CROI 2020
Dec 03, 2019
Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation
Sep 03, 2019
Viriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource Program
May 14, 2019
Hilliard & Shadowen, LLP Report Coalition Of Consumers, Activists, And Payors Sues Gilead And Other Manufacturers For Anticompetitive Practices On HIV Medicines
Apr 17, 2019
Global Antiretroviral Market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 - 2023
Apr 09, 2019
Global Antiretroviral Drugs Market 2013-2019 & 2023 - Multi-Class Drug Combinations are Predicted to Hold their Dominant Position in the Market
Nov 15, 2018
Global HIV Diagnostics and Therapeutics Markets Report 2018-2023 Featuring Abbott Laboratories, Bio-Rad Laboratories, Cipla, GSK, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific
Aug 15, 2018
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1
Jul 20, 2018
Global HIV Drugs Market 2018-2023: Key Players are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
Mar 28, 2018
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Nov 21, 2017
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
Nov 21, 2017
Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection
Jul 25, 2017
Viriom Obtains First Market Approval of Elsulfavirine (Elpida®) for Treatment of HIV-1 Infection in Russia